Open AccessAnticoagulation in COVID-19.
Author(s) -
Ximena Veloz Ochoa,
Gustavo Ayo Chipantasig,
Dixon Zambrano Palma
Publication year - 2021
Publication title -
international journal of medical and biomedical studies
Language(s) - English
Resource type - Journals
eISSN - 2589-8698
pISSN - 2589-868X
DOI - 10.32553/ijmbs.v5i2.1686
Subject(s) - heparin , coagulopathy , medicine , covid-19 , intensive care medicine , cytokine storm , thrombosis , pandemic , adverse effect , cytokine release syndrome , anticoagulant , disease , infectious disease (medical specialty) , virology , outbreak
In 2020 declared the COVID-19 pandemic. A new SARS-Cov-2 betacoronavirus transmitted through respiratory secretions of infected people, causing lesions in the pulmonary microvasculature, endothelial activation, massive release of pro-inflammatory substances "cytokine storm", which lead to a procoagulant state and on which it will depend the development of the serious disease. The management of coagulopathy induced by COVID-19 entails stratifying the risk of thrombosis, for which heparins are the treatment of choice, especially in hospitalized patients. Low molecular weight heparin (LMWH) is the first option since its administration implies longer times and less exposure of health personnel. Unfractionated heparin is another alternative but requires laboratory controls and is sometimes not available. Heparin-induced thrombocytopenia (HIT) and bleeding are serious adverse events secondary to the use of heparin anticoagulation.